MY136382A - Use of cholesterol-lowering agent - Google Patents
Use of cholesterol-lowering agentInfo
- Publication number
- MY136382A MY136382A MYPI20000415A MYPI20000415A MY136382A MY 136382 A MY136382 A MY 136382A MY PI20000415 A MYPI20000415 A MY PI20000415A MY PI20000415 A MYPI20000415 A MY PI20000415A MY 136382 A MY136382 A MY 136382A
- Authority
- MY
- Malaysia
- Prior art keywords
- compound
- cholesterol
- lowering agent
- lipid
- pyramidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
THE INVENTION CONCERNS THE USE OF PARTICULAR ORAL DOSAGE RANGES OF THE COMPOUND (E)-7-[4-FLUOROPHENYL) -6-ISOPROPYL -2- [METHYL (METHYLSULFONYL) AMINO] PYRAMIDIN-5-YL]-(3R, 5S)-3,5-DIHYDROXYHEPT -6-ENOIC ACID OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, TO ALTER BENEFICIALLY LIPID LEVELS OR LIPID RATIONS IN A HUMAN PATIENT IN NEED THEREOF, AS WELL AS HARMACEUTICAL COMPOSITIONS OF SAID COMPOUND OR SALTS ADAPTED FOR ORAL ADMINISTRATION WHICH COMPRISE SUCH DOSAGES, AND METHODS OF PREPARATION THEREOF.FIG 1-MOST ILLUSTRATIVE DRAWINGS. (FIG.1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902590.0A GB9902590D0 (en) | 1999-02-06 | 1999-02-06 | Use of cholesterol-lowering agent |
| GBGB9921062.7A GB9921062D0 (en) | 1999-09-08 | 1999-09-08 | Use of cholestrol-lowering agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY136382A true MY136382A (en) | 2008-09-30 |
Family
ID=26315084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20000415A MY136382A (en) | 1999-02-06 | 2000-02-04 | Use of cholesterol-lowering agent |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1150679A1 (en) |
| JP (2) | JP2002536333A (en) |
| KR (1) | KR100699287B1 (en) |
| CN (1) | CN1347320A (en) |
| AR (1) | AR022462A1 (en) |
| AU (1) | AU769897B2 (en) |
| BR (1) | BR0007991A (en) |
| CA (1) | CA2358641A1 (en) |
| CZ (1) | CZ20012631A3 (en) |
| EE (1) | EE04659B1 (en) |
| HK (1) | HK1040924A1 (en) |
| HU (1) | HUP0105019A3 (en) |
| ID (1) | ID30131A (en) |
| IL (1) | IL144662A0 (en) |
| IS (1) | IS5996A (en) |
| MY (1) | MY136382A (en) |
| NO (1) | NO319827B1 (en) |
| NZ (1) | NZ512681A (en) |
| PL (1) | PL349137A1 (en) |
| SK (1) | SK11112001A3 (en) |
| TR (1) | TR200102236T2 (en) |
| WO (1) | WO2000045819A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| SE0103509D0 (en) * | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre-demented states |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2007142581A1 (en) * | 2006-06-07 | 2007-12-13 | Astrazeneca Ab | Combination product for the treatment or prevention of dyslipidaemia |
| US8436028B2 (en) | 2007-06-20 | 2013-05-07 | Merck Sharp & Dohme Corp | CETP inhibitors derived from benzoxazole arylamides |
| US8293721B2 (en) | 2007-06-20 | 2012-10-23 | Merck Sharpe & Dohme Corp. | CETP inhibitors derived from benzoxazole arylamides |
| WO2008156715A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Cetp inhibitors derived from benzoxazole arylamides |
| EP2216095A1 (en) * | 2009-01-27 | 2010-08-11 | Koninklijke Philips Electronics N.V. | Microfluidic device for full blood count |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260446A (en) * | 1989-12-22 | 1993-11-09 | Basf Aktiengesellschaft | Aminothiazoles |
| JP2648897B2 (en) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
-
2000
- 2000-01-31 AR ARP000100408A patent/AR022462A1/en unknown
- 2000-02-01 WO PCT/GB2000/000285 patent/WO2000045819A1/en active IP Right Grant
- 2000-02-01 ID IDW00200101666A patent/ID30131A/en unknown
- 2000-02-01 KR KR1020017009822A patent/KR100699287B1/en active IP Right Review Request
- 2000-02-01 JP JP2000596939A patent/JP2002536333A/en not_active Withdrawn
- 2000-02-01 EP EP00901748A patent/EP1150679A1/en not_active Withdrawn
- 2000-02-01 CA CA002358641A patent/CA2358641A1/en not_active Abandoned
- 2000-02-01 AU AU23051/00A patent/AU769897B2/en not_active Revoked
- 2000-02-01 CN CN00803519A patent/CN1347320A/en active Pending
- 2000-02-01 IL IL14466200A patent/IL144662A0/en unknown
- 2000-02-01 BR BR0007991-0A patent/BR0007991A/en not_active Application Discontinuation
- 2000-02-01 EE EEP200100404A patent/EE04659B1/en not_active IP Right Cessation
- 2000-02-01 HU HU0105019A patent/HUP0105019A3/en unknown
- 2000-02-01 TR TR2001/02236T patent/TR200102236T2/en unknown
- 2000-02-01 NZ NZ512681A patent/NZ512681A/en not_active IP Right Cessation
- 2000-02-01 CZ CZ20012631A patent/CZ20012631A3/en unknown
- 2000-02-01 SK SK1111-2001A patent/SK11112001A3/en not_active Application Discontinuation
- 2000-02-01 PL PL00349137A patent/PL349137A1/en not_active Application Discontinuation
- 2000-02-04 MY MYPI20000415A patent/MY136382A/en unknown
-
2001
- 2001-07-10 IS IS5996A patent/IS5996A/en unknown
- 2001-08-03 NO NO20013810A patent/NO319827B1/en active IP Right Review Request
-
2002
- 2002-04-10 HK HK02102713.0A patent/HK1040924A1/en unknown
-
2011
- 2011-02-22 JP JP2011035406A patent/JP2011137023A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR0007991A (en) | 2001-11-06 |
| HUP0105019A3 (en) | 2003-02-28 |
| NO319827B1 (en) | 2005-09-19 |
| CZ20012631A3 (en) | 2001-10-17 |
| WO2000045819A1 (en) | 2000-08-10 |
| HK1040924A1 (en) | 2002-06-28 |
| PL349137A1 (en) | 2002-07-01 |
| JP2011137023A (en) | 2011-07-14 |
| AU769897B2 (en) | 2004-02-05 |
| NO20013810L (en) | 2001-10-03 |
| EE04659B1 (en) | 2006-08-15 |
| NZ512681A (en) | 2003-12-19 |
| TR200102236T2 (en) | 2001-12-21 |
| ID30131A (en) | 2001-11-08 |
| AU2305100A (en) | 2000-08-25 |
| AR022462A1 (en) | 2002-09-04 |
| CN1347320A (en) | 2002-05-01 |
| IS5996A (en) | 2001-07-10 |
| CA2358641A1 (en) | 2000-08-10 |
| IL144662A0 (en) | 2002-05-23 |
| SK11112001A3 (en) | 2002-02-05 |
| KR100699287B1 (en) | 2007-03-26 |
| HUP0105019A2 (en) | 2002-05-29 |
| JP2002536333A (en) | 2002-10-29 |
| KR20010089631A (en) | 2001-10-06 |
| NO20013810D0 (en) | 2001-08-03 |
| EE200100404A (en) | 2002-10-15 |
| EP1150679A1 (en) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL155919A (en) | (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia | |
| CR10114A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INHIBITORS OF HMG COA REDUCTASA (DIVISIONAL OF EXP. 6687) | |
| LU90956I2 (en) | Metvix active ingredient methylaminolevulinic in the form of a salt preferably methylaminolevulinic hydrochloride | |
| EA200301165A1 (en) | Drug on the basis of oxycodone | |
| DK1383752T3 (en) | Deuterated 3-piperidinopropiophenones as well as drugs containing these compounds | |
| DE60323958D1 (en) | BUPRENORPHINE CONTAINING PREPARATION | |
| BG105459A (en) | Pharmaceutical moxifloxacin preparation | |
| LT2001119A (en) | Pharmaceutical formulations comprising intranasal morphine and use thereof | |
| NO20063277L (en) | Pharmaceutical composition of vinflunine intended for parenteral administration, preparation and use thereof | |
| WO2000078294A3 (en) | Oral administration form for administering a fixed tramadol and diclofenac combination | |
| TR200002969T2 (en) | Pharmaceutical composition. | |
| MY136382A (en) | Use of cholesterol-lowering agent | |
| BG104797A (en) | Use of dexmedetomi dine for sedative effect in patients in an intensive care unit | |
| DK1228758T3 (en) | Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease | |
| UY27373A1 (en) | BETA-HUMAN INTERFER FORMULATIONS | |
| JP2002536333A5 (en) | ||
| MXPA05012299A (en) | Pharmaceutical composition comprising valsartan. | |
| MY134059A (en) | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts | |
| RU2004112422A (en) | ROUVASTATIN IN PREDEDENTIONAL CONDITIONS | |
| GEP20043377B (en) | Pharmaceutical Complex | |
| TH68542A (en) | The use of cholesterol-lowering agents | |
| TH88724B (en) | Treatment | |
| TH88724A (en) | Treatment | |
| HUP0103459A2 (en) | Oral dosage formulations comprising (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid | |
| BR0013921A (en) | Pharmaceutical compositions for the treatment of psoriasis |